Press Releases

A new collaboration will see Roswell Park Comprehensive Cancer Center partnering with the University of New Mexico (UNM), supported by a grant from the Bristol Myers Squibb Foundation, to address health disparities for the Pueblo Nations of New Mexico.

New research led by Roswell Park’s Brian Betts, MD, shows that adding a JAK inhibitor to standard treatment did not improve GvHD prevention for patients with hematologic cancers. Further research is warranted to determine whether this strategy might benefit patients who experience the chronic, more widely systemic form of GVHD.

New research led by Roswell Park experts in health behavior suggests that daily e-cigarette use may help some people to quit using combustible cigarettes.

Roswell Park made its debut on the Forbes list of America’s Best Employers for Women 2024, ranking in the top one-quarter among the 600 organizations included. Roswell Park is one of only three cancer centers nationally to be recognized with this prestigious distinction, which is presented by Forbes and Statista Inc.

Roswell Park has appointed five new leaders overseeing various aspects of patient care and supportive services. One is new to Roswell Park, while three are clinical team members promoted to new roles.

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation awarded to MimiVax Inc. now applies to SurVaxM as treatment for not just adult glioblastoma but a broader category of cancerous brain tumors: any malignant glioma in children or adults.

A team of Roswell Park experts led by Hemn Mohammadpour, DVM, PhD, conducted research that offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published in the journal Cellular & Molecular Immunology.

A research effort led by Dean Tang, PhD, sheds light on a critical area of oncologic study — the biology and mechanisms behind castration-resistant prostate cancer. The team’s findings, published in the journal Cell Stem Cell, reflect six years of collaborative research.

The 2024 Warren Alpert Foundation Prize has been awarded to Renier Brentjens, MD, PhD, and three other scientists whose transformational discoveries led to the creation of chimeric antigen receptor (CAR) T cells, a treatment that modifies patients’ immune cells and optimizes their ability to eliminate cancer cells.